Motus GI to Release First Quarter 2020 Results and Provide a Business Update on May 14th
FORT LAUDERDALE, Fla., May 04, 2020 (GLOBE NEWSWIRE) -- , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
| Conference Call and Webcast | |
| Date and Time: | May 14th at 4:30 p.m. ET |
| Domestic: | 877-407-0792 |
| International: | 201-689-8263 |
| Passcode: | 13702032 |
| Webcast: | or |
A replay of the webcast will be archived on the Motus GI website, , for 90 days following the event.
About Motus GI and the Pure-Vu® System
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to improve visualization during a colonoscopy while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better quality exam. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and enhancing the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.
For more information, visit and connect with the Company on , and .
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
Media Contact:
Gloria Gasaatura
LifeSci Public Relations
(646) 627-8387
